Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
The American Association for Cancer Research (AACR) annual meeting highlighted the latest direction of early‑stage drug development. This year’s sessions featured two prostate‑cancer candidates using mechanisms that were not in the clinic just eighteen months ago. The preview spotlights a wave of novel modalities—such as RNA‑targeted agents and bispecific antibodies—aimed at metastatic disease. The personal relevance underscores the urgency, as metastatic prostate cancer remains a leading cause of mortality.
Researchers at Johns Hopkins created patient‑specific digital heart twins that simulate electrical activity to plan ventricular tachycardia ablations. By converting high‑resolution MRI scans into 3‑D models, physicians could test virtual ablations and identify optimal targets before entering the operating room....
The FDA has published a curated list of frequently requested and proactively released drug‑specific records, spanning from 2016 to 2026. The collection includes letters on hemp‑derived cannabidiol research, a tirzepatide injection shortage resolution, the JAYPIRCA approval package, and numerous REMS...
Olezarsen, an antisense drug targeting APOC3, dramatically lowered triglycerides (‑64 %) and remnant cholesterol (‑72 %) in the Phase III Essence‑TIMI 73b trial, yet a 12‑month coronary CTA subanalysis showed no significant reduction in non‑calcified plaque volume versus placebo. The study involved 468 patients...
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
A Wisconsin man, Tim Friede, let venomous snakes bite him for two decades, building a unique repertoire of antitoxin antibodies. Researchers at biotech firm Centivax isolated two of these antibodies and combined them with the toxin‑blocking drug varespladib, creating a...
FDA Commissioner Marty Makary said the agency will slash the amount of non‑safety data required to launch new drug trials in the United States. The streamlined approach aims to eliminate redundant paperwork, focusing only on safety‑related information. Makary framed the...
Scientists at Israel's Weizmann Institute have engineered tobacco (Nicotiana benthamiana) to produce five psychedelic compounds—including psilocin, psilocybin, DMT, bufotenin and 5‑methoxy‑DMT—using agroinfiltration, a transient gene‑delivery method that does not integrate DNA into the plant genome. The approach leverages nine introduced...
A 2025 Nature Medicine study showed that delivering a functional OTOF gene via an adeno‑associated virus dramatically improves hearing in patients with genetic deafness. Ten participants aged 1 to 24 across five Chinese hospitals experienced a reduction in hearing threshold...
Researchers in Brazil have created a graphene‑based scaffold that repaired nearly 90% of bone fractures in rats within a month, outperforming existing biomaterials. The scaffold combines graphene with chitosan‑xanthan polymers derived from waste black liquor, a pulp‑and‑paper by‑product. Acting as...
Researchers used high‑throughput phage display sequencing to map the protein landscape of germ cell tumors, uncovering a distinct molecular signature that differentiates malignant from benign testicular tissue. The study, led by a collaborative team from NYU Abu Dhabi and the...
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Researchers have conducted the largest genome‑wide association study (GWAS) to date using objective sleep metrics captured by accelerometer‑based wearables. By harmonizing millions of device‑derived sleep measurements with genotyping data, they identified dozens of novel genetic loci tied to duration, efficiency,...
Researchers at Charité have created a hair‑based diagnostic that reads the activity of 17 clock‑related genes to pinpoint an individual’s chronotype. In a study of over 4,000 volunteers, the test showed that lifestyle factors—especially employment—shift internal clocks more than genetics...
Researchers at Icahn School of Medicine discovered that the aryl hydrocarbon receptor (AHR) acts as a molecular brake preventing axon regeneration after nerve injury. Genetic deletion or pharmacological inhibition of AHR in mouse models redirected neurons from a stress‑survival mode...
Novo Nordisk announced it will cut approximately 400 positions at its recently acquired Bloomington, Indiana manufacturing plant. The cuts follow FDA rejections of drug products from three contract companies that used the facility, citing manufacturing deficiencies. The issues stem from...
Catherine and James Galbraith at Oregon Health & Science University identified a previously unknown intracellular fluid‑flow system—dubbed “cellular winds”—that actively pushes proteins toward a cell’s leading edge. Published in Nature Communications, the finding challenges diffusion‑based textbook models and offers a...
HCW Biologics Inc. filed an appeal to Nasdaq over a minimum bid‑price compliance notice and announced that Phase 1 results for its lead immunotherapy HCW9302 are slated for the first half of 2026. The appeal follows a 5.56% drop in the...
Researchers at the University of Delaware and Waters have created an automated text‑mining pipeline that extracts relationships between cell‑culture conditions and protein glycosylation with 88% accuracy. The extracted data are normalized and stored in a Bioprocess Knowledge Graph, enabling a...
Researchers have demonstrated that the peptide‑based surfactant Peptonic ih‑T1010 performs on par with the industry‑standard poloxamer 188 in CHO and HEK293 fed‑batch cultures for monoclonal antibodies and AAV vectors. The new surfactant dramatically reduces foam formation, allowing manufacturers to skip...
The Trump administration has postponed filing an appeal against a federal judge’s injunction on RFK Jr.’s vaccine policy overhaul, citing internal debates over election‑year politics. Meanwhile, Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a premium of...
Emerging platforms are converging on a universal influenza vaccine, aiming to replace strain‑specific shots that require yearly reformulation. Companies such as Versatope are leveraging engineered bacterial outer‑membrane vesicles to deliver precise antigens, while NIH’s FluMos‑v2 expands hemagglutinin coverage to six...
Amgen and China‑based Zai Lab have announced a Phase 1b clinical study that combines Amgen’s T‑cell engager Imdelltra with Zai Lab’s experimental antibody‑drug conjugate zocilurtatug pelitecan, targeting the DLL3 protein in aggressive neuroendocrine cancers. The trial will evaluate safety and early...
Routine genomic testing with Agendia’s MammaPrint and BluePrint can narrow the long‑standing survival gap between Black and white women with early‑stage, hormone‑receptor‑positive breast cancer. In a study of more than 1,000 matched patients, Black women were twice as likely to...
Paragon Therapeutics is spinning out its Alzheimer’s-focused unit, Korsana Biosciences, via a reverse merger that will list the company on a U.S. exchange. The deal, championed by Paragon co‑founder Jonathan Violin, merges Korsana with a publicly traded shell, providing immediate...
Gene‑therapy manufacturers face a bottleneck when adding large volumes of AAV transfection complex to bioreactors within a narrow time window. Mirus Bio’s VirusGEN Transfection Complex Stabilizer, used with TransIT‑VirusGEN reagent, cuts the required complex volume from roughly five percent to...
The World Health Organization released its International Nonproprietary Names (INN) Proposed List 134, introducing 124 new drug names slated for future approval. The list features a notable influx of antiviral and oncology agents, as well as the first biosimilar designations...
A 20‑year‑old asthma medication, Xolair (omalizumab), is now accelerating food‑allergy research, especially for peanut sensitivities. Recent clinical trials combined the drug with oral immunotherapy, cutting severe reaction rates by roughly 70 percent. The FDA has recently cleared the first oral...
Danish biotech IO Biotech announced it will file for Chapter 11 bankruptcy after its lead cancer vaccine failed to demonstrate efficacy in a pivotal trial. The vaccine, designed to treat aggressive solid tumors, showed no statistically significant benefit, prompting the...
Nvidia’s GTC keynote highlighted a new wave of agentic AI systems—OpenClaw, Kosmos, LabOS, Latent‑Y and Dyno Psi‑Phi—designed to automate and accelerate scientific discovery. These agents combine large‑language models, XR interfaces and robotic labs to compress months of research into days while...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
If FDA does this, which is highly likely succumbing to pressure from RFK Jr, it crosses a new red line and, as far as I know, is unprecedented. Lifting a ban on drugs that are injected into the bloodstream without...
NAD+ controls circadian rhythmicity during cardiac aging https://t.co/NNVx94IIC8 Fig. 2: Cardiac NAD+ decreases with aging, with restoration by supplementation with nicotinamide riboside. https://t.co/z4uSqKrYjR
Insilico Medicine, a veteran AI‑driven drug discovery firm, announced a partnership with Eli Lilly that includes a $115 million upfront payment and up to $2.75 billion in milestone‑based total consideration. The deal leverages Insilico’s generative‑AI platform to co‑develop novel therapeutics, primarily targeting metabolic...
Longevity 2.0: Your next doctor won't prescribe pills—they'll prescribe gene therapies, epigenetic reprogramming, and personalized longevity protocols. Medicine is shifting from "treat symptoms" to "reverse aging at the cellular level."
Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies https://t.co/DMVxerI64T https://t.co/TUPGK6SqUK
Eleven early‑stage life‑sciences startups were chosen for the Drive accelerator, with eight headquartered in Massachusetts and the remaining three in South Carolina. MassBio will manage the biotech cohort while SCbio leads the biomarkers and diagnostics group. The free eight‑week program...
Another feature adding to my terminal plasmid editor is a transcriptome browser. Helps you quickly build blast databases from a heap of transcripts in a single fasta file. Gonna add HMM/Pfam detection and Pfam search. I really love this current...
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Q1 2026 biopharma saw a wave of mega‑size M&A, with deals like Boston Scientific’s $14.5 billion purchase of Penumbra and Eli Lilly’s $7.8 billion acquisition of Centessa, underscoring a strategic push for precision platforms. The quarter also delivered a string of rare‑disease approvals—Zycubo,...
A team led by Kim et al. reported that homoharringtonine (HHT) acts as a senolytic, extending lifespan and reversing diet‑induced obesity in mice. The findings, published in Nature Communications, suggest a repurposed cancer drug could become a cornerstone of longevity...
Abbisko Therapeutics announced that the European Medicines Agency granted orphan‑drug designation to its oral FGFR4 inhibitor irpagratinib for hepatocellular carcinoma. The milestone adds to earlier U.S. designations and comes as the company also secures FDA IND clearance for its FGFR2/3...
RenovoRx announced a widened FY25 net loss of $11.2 million, up from $8.8 million a year earlier, while posting its first full year of revenue from the FDA‑cleared RenovoCath device. The company also said it expects to complete enrollment for its Phase III...
The NHS has secured a cost‑effective deal with Novo Nordisk to make the GLP‑1 drug Wegovy available to over 1 million English adults who have suffered a heart attack, stroke or peripheral arterial disease and have a BMI of 27 or...
Spectrum Spine Inc announced that its BioBraille™ surface technology has received FDA clearance, making it the first orthopedic implant to be designated as a nanotechnology device. The clearance covers an anterior cervical cage and paves the way for a broader...
Pfizer's shares rose about 0.7% to $27.97 after the company reported positive Phase 3 data for its Talzenna‑Xtandi combo in metastatic prostate cancer and encouraging mid‑stage breast cancer results. The gains came despite a 2026 revenue outlook that is essentially...
Merck announced a definitive agreement to buy California‑based cancer biotech Terns Pharmaceuticals for an estimated equity value of $6.7 billion. The deal, slated to close in Q2 2026, expands Merck’s hematology pipeline and underscores a rapid M&A cadence designed to cushion the...
